First-in-Class Small Molecule Inhibitor of Oncogene AVIL in Glioblastoma
DNA and Cell Biology · 01.06.2026 · 45 (6) · 263-266
DOI: 10.1177/10445498261431994 ↗Kurz gefasst
Fachartikel in der Zeitschrift DNA and Cell Biology, online erschienen am 10.03.2026. Verfasst von Zhongqiu Xie und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, School of Medicine, University of Virginia, Charlottesville, Virginia, USA. Hauptthemen laut MEDLINE: Glioblastoma, Brain Neoplasms, Microfilament Proteins, Antineoplastic Agents. Die Arbeit nennt 11 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Cancer Institute, Ben and Catherine Ivy Foundation.
Abstract (Originalsprache)
Glioblastoma multiforme (GBM) is the most prevalent and aggressive malignant primary brain tumor, marked by rapid growth, extensive invasiveness, and a median survival of only ∼15 months despite current multimodal therapy. To identify new therapeutic vulnerabilities, we investigated the actin-regulatory protein AVIL , previously implicated through a MARS-AVIL gene fusion in rhabdomyosarcoma. Comprehensive genomic and transcriptomic analyses across REMBRANDT, TCGA, and CGGA datasets revealed recurrent AVIL amplification and consistently elevated AVIL expression in GBM compared with normal brain tissue. AVIL was overexpressed across all GBM molecular subtypes and glioma stem cell (GSC) states but was nearly undetectable in normal astrocytes, neural stem cells, and brain tissues. Functional studies demonstrated that AVIL is both necessary and sufficient for glioma genesis: AVIL silencing eradicated GBM cells in vitro and suppressed xenograft growth in vivo , while AVIL overexpression enhanced proliferation, migration, and transformation. Mechanistically, AVIL drives tumor progression through actin cytoskeleton remodeling and activation of the FOXM1-LIN28B oncogenic pathway. Using a small molecule microarray screen, we identified a selective AVIL -binding compound (compound A) that potently inhibited GBM cell growth with minimal toxicity to normal astrocytes. Gene expression changes induced by compound A mirrored those following AVIL knockdown, indicating on-target activity. Compound A demonstrated robust antitumor efficacy in multiple preclinical GBM models, including orthotopic xenografts, GSC-derived tumors, patient-derived xenografts, and temozolomide-resistant GBM with favorable pharmacokinetics and blood–brain barrier penetration. The minimal AVIL expression in normal tissues and lack of phenotype in AVIL -deficient mice underscore its potential as a low-toxicity therapeutic target. Together, these findings establish AVIL as a critical oncogenic driver in GBM and introduce a first-in-class AVIL inhibitor with strong translational promise for precision neuro-oncology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, School of Medicine, University of Virginia, Charlottesville, Virginia, USA.
- Department of Biochemistry and Molecular Genetics, University of Virginia, Charlottesville, Virginia, USA.
ORCID-Profile: Hui Li
Förderung
- NCI NIH HHS
- National Cancer Institute
- Ben and Catherine Ivy Foundation
Zitieren
APA
Xie, Z., Xie, S., & Li, H. (2026). First-in-Class Small Molecule Inhibitor of Oncogene AVIL in Glioblastoma. DNA and Cell Biology, 45(6), 263-266. https://doi.org/10.1177/10445498261431994
Vancouver
Xie Z, Xie S, Li H. First-in-Class Small Molecule Inhibitor of Oncogene AVIL in Glioblastoma. DNA and Cell Biology. 2026;45(6):263-266. doi:10.1177/10445498261431994
BibTeX
@article{Xie2026,
author = {Xie, Zhongqiu and Xie, Sophia and Li, Hui},
title = {First-in-Class Small Molecule Inhibitor of Oncogene AVIL in Glioblastoma},
journal = {DNA and Cell Biology},
year = {2026},
volume = {45},
number = {6},
pages = {263--266},
doi = {10.1177/10445498261431994}
}
EUVIMED